Intracellular bacterial targets

Intracellular bacterial targets encompass a broad range of molecular components within pathogens that survive and replicate inside host cells, such as Mycobacterium tuberculosis, Chlamydia trachomatis, and Listeria monocytogenes (PubMed: 25227486). These targets include essential bacterial machinery such as the ribosome, which is inhibited by macrolides and tetracyclines, and RNA polymerase, which is targeted by rifamycins (StatPearls: NBK430925). Because these bacteria reside within specialized host compartments like phagosomes or the cytosol, effective drugs must possess specific pharmacokinetic properties to penetrate host membranes and maintain activity in acidic or enzymatic environments (NIH: PMC3537113). Targeting these molecules is critical for treating chronic and latent infections where bacteria evade the extracellular immune response. However, the requirement for high intracellular drug concentrations often poses risks of host cell toxicity and the development of antimicrobial resistance (PubMed: 30245130). Consequently, drug development for these targets often focuses on enhancing lipophilicity or utilizing specialized delivery systems to ensure effective intracellular accumulation.

Other names

Intracellular pathogen targetsBacterial intracellular targetsTargets of intracellular bacteria

Drugs targeting intracellular bacteria work through various mechanisms including the inhibition of DNA-dependent RNA polymerase (rifamycins), inhibition of the 30S or 50S ribosomal subunits to disrupt protein synthesis (tetracyclines, macrolides), inhibition of DNA gyrase and topoisomerase IV (fluoroquinolones), and disruption of cell wall components like mycolic acid (isoniazid) (StatPearls: NBK430925, PubMed: 25227486).